Use of SGLT2 Inhibitors in Patients With Type 2 Diabetes and Chronic Kidney Disease-A Multi-Country Report from the FOUNTAIN Platform

被引：0

作者：

Johannes, Catherine B. ^{[1
]}

Ziemiecki, Ryan ^{[1
]}

Pladevall-Vila, Manel ^{[1
]}

Kosvesdy, Csaba P. ^{[2
]}

Ebert, Natalie ^{[3
]}

Thomsen, Reimar W. W. ^{[4
,5
]}

Christiansen, Christian Fynbo ^{[4
,5
]}

Baak, Brenda ^{[6
]}

Robles Cabaninas, Celia ^{[7
]}

Kashihara, Naoki ^{[8
]}

Yano, Yuichiro ^{[9
]}

Kanegae, Hiroshi ^{[10
]}

Coleman, Craig I. ^{[11
]}

Okami, Suguru ^{[12
]}

Liu, Fangfang ^{[13
]}

Layton, J. Bradley ^{[1
]}

Vizcaya, David ^{[13
]}

Oberprieler, Nikolaus G. ^{[13
]}

机构：

[1] Res Triangle Inst Hlth Solut, Res Triangle Pk, NC USA

[2] Univ Tennessee, Hlth Sci Ctr, Knoxville, TN USA

[3] Charite Univ Med Berlin, Inst Publ Hlth, Berlin, Germany

[4] Aarhus Univ, Dept Clin Epidemiol, Aarhus, Denmark

[5] Aarhus Univ Hosp, Aarhus, Denmark

[6] PHARMO Inst Drug Outcomes Res, Utrecht, Netherlands

[7] FISABIO, Valencia, Spain

[8] Kawasaki Med Sch, Kurashiki, Okayama, Japan

[9] Juntendo Univ, Fac Med, Tokyo, Japan

[10] Genki Plaza Med Ctr Hlth Care, Tokyo, Japan

[11] Univ Connecticut, Storrs, CT USA

[12] Bayer Yakuhin Ltd, Osaka, Japan

[13] Bayer AG, Leverkusen, Germany

来源：

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2024年 / 33卷

关键词：

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

568

引用

页码：237 / 238

页数：2

共 50 条

[1] The effects of the SGLT2 inhibitors on the Japanese type 2 diabetes patients with chronic kidney disease
Kobayashi, K.
Sato, K.
Hatori, N.
Miyakawa, M.
Toyoda, M.
DIABETOLOGIA, 2017, 60 : S418 - S418
[2] Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
Scheen, Andre J.
CLINICAL PHARMACOKINETICS, 2015, 54 (07) : 691 - 708
[3] The Kidney Effects of the SGLT2 Inhibitors on the Japanese Type 2 Diabetes Mellitus Patients with Chronic Kidney Disease
Kobayashi, Kazuo
Toyoda, Masao
Hatori, Nobuo
Sakai, Hiroyuki
Furuki, Takayuki
Tamura, Kouichi
Miyakawa, Masaaki
DIABETES, 2019, 68
[4] Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
André J. Scheen
Clinical Pharmacokinetics, 2015, 54 : 691 - 708
[5] SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes
David C. Wheeler
June James
Dipesh Patel
Adie Viljoen
Amar Ali
Marc Evans
Kevin Fernando
Debbie Hicks
Nicola Milne
Philip Newland-Jones
John Wilding
Diabetes Therapy, 2020, 11 : 2757 - 2774
[6] SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes
Wheeler, David C.
James, June
Patel, Dipesh
Viljoen, Adie
Ali, Amar
Evans, Marc
Fernando, Kevin
Hicks, Debbie
Milne, Nicola
Newland-Jones, Philip
Wilding, John
DIABETES THERAPY, 2020, 11 (12) : 2757 - 2774
[7] Understanding the protective effects of SGLT2 inhibitors in type 2 diabetes patients with chronic kidney disease
Scheen, Andre J.
Delanaye, Pierre
EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2022, 17 (01) : 35 - 46
[8] Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease
Scheen, Andre J.
EXPERT OPINION ON DRUG SAFETY, 2020, 19 (03) : 243 - 256
[9] Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease
Kelly, Michael S.
Lewis, Jelena
Huntsberry, Ashley M.
Dea, Lauren
Portillo, Ivan
POSTGRADUATE MEDICINE, 2019, 131 (01) : 31 - 42
[10] SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease
Kanduri, Swetha R.
Kovvuru, Karthik
Hansrivijit, Panupong
Thongprayoon, Charat
Vallabhajosyula, Saraschandra
Pivovarova, Aleksandra I.
Chewcharat, Api
Garla, Vishnu
Medaura, Juan
Cheungpasitporn, Wisit
JOURNAL OF CLINICAL MEDICINE, 2020, 9 (09)

← 1 2 3 4 5 →